No connection

Search Results

ABBV vs INBS

ABBV
AbbVie Inc.
NEUTRAL
Price
$219.26
Market Cap
$387.52B
Sector
Healthcare
AI Confidence
68%
INBS
Intelligent Bio Solutions Inc.
BEARISH
Price
$2.46
Market Cap
$4.9M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
ABBV
163.63
INBS
--
Forward P/E
ABBV
15.42
INBS
7.03
P/B Ratio
ABBV
-146.66
INBS
0.27
P/S Ratio
ABBV
6.5
INBS
1.37
EV/EBITDA
ABBV
15.27
INBS
-0.5

Profitability

Gross Margin
ABBV
71.46%
INBS
46.21%
Operating Margin
ABBV
35.5%
INBS
-290.89%
Profit Margin
ABBV
4.0%
INBS
0.0%
ROE
ABBV
137.96%
INBS
-150.2%
ROA
ABBV
9.59%
INBS
-51.17%

Growth

Revenue Growth
ABBV
9.1%
INBS
47.6%
Earnings Growth
ABBV
-88.7%
INBS
--

Financial Health

Debt/Equity
ABBV
--
INBS
0.18
Current Ratio
ABBV
0.72
INBS
2.38
Quick Ratio
ABBV
0.47
INBS
2.17

Dividends

Dividend Yield
ABBV
3.05%
INBS
--
Payout Ratio
ABBV
490.15%
INBS
0.0%

AI Verdict

ABBV NEUTRAL

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Strengths
High operating margin (35.50%) indicating strong pricing power and cost control
Consistent revenue growth (9.10% YoY) outpacing sector average
Strong track record of earnings surprises (22 out of 25 quarters beat estimates)
Risks
Extremely high P/E ratio (163.63) vs forward P/E (15.42), suggesting potential overvaluation on trailing basis
Earnings growth collapsing (YoY: -88.70%, Q/Q: -88.10%) indicating severe profitability deterioration
Unsustainable dividend payout ratio (490.15%) threatening dividend security
INBS BEARISH

The company exhibits severe fundamental distress, highlighted by a Piotroski F-Score of 1/9, indicating critical weakness in financial health. While revenue growth is strong at 47.6% and the balance sheet shows low debt (D/E 0.18), these are overshadowed by an operating margin of -290.89% and a total collapse in share price, which is currently at its 52-week low. The stock is in a clear technical downtrend with a 1-year return of -79.8%, suggesting a lack of investor confidence despite the low Price-to-Book ratio.

Strengths
Strong YoY revenue growth of 47.60%
Low Debt-to-Equity ratio (0.18)
Healthy liquidity with a Current Ratio of 2.38
Risks
Critical financial health (Piotroski F-Score 1/9)
Extreme operating losses (Operating Margin -290.89%)
Severe price depreciation (down 79.8% over 1 year)

Compare Another Pair

ABBV vs INBS: Head-to-Head Comparison

This page compares AbbVie Inc. (ABBV) and Intelligent Bio Solutions Inc. (INBS) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile